Peter Kuhn – “The Fluid Phase of Solid Tumors: How does cancer spread?”
Speaker: Peter Kuhn, PhD. founded the Scripps Physics Oncology Center with its core research program at the Kuhn Lab. He is a scientist and entrepreneur with a career long commitment in personalized healthcare and individualized cancer patient care. Dr. Kuhn is a physicist who trained at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he later joined the faculties of Medicine and Accelerator Physics. Since 2002 his primary faculty appointment is with Scripps Research in La Jolla, CA. Dr. Kuhn has co-authored of over 150 peer reviewed scientific publications and patents. Dr. Kuhn is a Director of the Scripps Physics Oncology Center where he is developing the concepts for lifelong diagnostic companions for cancer patients. Leveraging the fluid phase of solid tumors the Scripps Physics Oncology Center is advancing daily the forefront of both improving healthcare effectiveness by providing drug guidance and increasing our understanding of cancer as a disease in each individual patient.
Location: Biodesign Auditorium
Web Cast: View Web Cast Video
Date & Time: November 1st, 2012 12:00 p.m.
Title: The Fluid Phase of Solid Tumors: How does cancer spread?
Abstract: The fluid phase of solid tumors is a clinical tool in personalized cancer care and an emerging research tool in basic science cancer discoveries. The Scripps Physics Oncology Center developed a set of tools for probing the fluid phase. The leading tool is the HD-CTC assay with which we are undertaking a series of clinical studies investigating the metastatic pathways in cancer patients. We are now coupling the experimental data with a theoretical framework for a more complete description of the disease progression.
The fluid phase of solid tumors is a critical third microenvironment in the development and progression of carcinomas. Cells originating from primary or secondary sites travel through the blood circulatory system to either get cleared out or initiate new tumor growth. Translational research efforts are attempting to identify the various subtypes of circulating tumor cells (CTCs), their origins, their destinations and their impact on the disease. Understanding and characterizing CTCs is a first step towards utilizing them as both biopsy material and directly as a biomarker. It requires approaches of subtyping CTCs at the single cell level using molecular and cellular approaches.
Results will be presented that describe technical developments and validation, clinical validation and clinical utility of the HD-CTC Technology.
Thank you and if you have questions please contact Amanda Wilber! And don’t forget, coffee will be served!
Amanda Wilber, Center for the Convergence of Physical Science and Cancer Biology
Arizona State University | P.O. Box 871504 | Tempe, AZ 85287
480.965.3860 | Fax: 480.965.6362